Abstract
PARP (Poly [ADP-ribose] polymerase) enzyme has a critical role in base excision repair for DNA damage by RT and TMZ. Veliparib is an oral PARP inhibitor that potentiates RT and TMZ in preclinical glioma models. ABTC conducted a phase I safety and dose finding trial of Veliparib given concurrent with standard TMZ and RT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
